Actualizado Reviewed

Appendix A: Key to Acronyms

General Terms

Acronym/AbbreviationFull Name
AASLDAmerican Association for the Study of Liver Diseases
ACOGAmerican College of Obstetricians and Gynecologists
ACTGAIDS Clinical Trials Group
ALTalanine aminotransferase
anti-HBcanti-hepatitis B core antibody
anti-HBshepatitis B surface antibody
aORadjusted odds ratio
aHRadjusted hazard ratio
aRRadjusted risk ratio
ARTantiretroviral therapy
ARVantiretroviral
AUCarea under the curve
AUC0-24harea under the curve from 0 to 24 hours 
BMCbone mineral content
BMDbone mineral density
BSID IIIBayley Scales of Infant and Toddler Development, Third Edition
BMIbody mass index
BHIVABritish HIV Association
C12hconcentration at 12 hours postdose
C24hconcentration at 24 hours postdose
CARchimeric antigen receptor
cCMVcongenital cytomegalovirus
CCR5C-C chemokine receptor type 5
 
CD4CD4 T lymphocyte
CDCCenters for Disease Control and Prevention
CIconfidence interval
CKcreatine kinase
CL/Fapparent clearance
Cmaxmaximum plasma concentration
Cminminimum plasma concentration
CMVcytomegalovirus
Ctroughtrough concentration
CNSCOCcentral nervous systemcombined oral contraceptives
COCcombined oral contraceptives
COC/P/Rcombined oral contraceptives/patch/ring
CrClcreatinine clearance
CYPcytochrome P450
CYP3A4cytochrome P450 3A4
DAAdirect-acting antiviral
DBSdried blood spots
DMCDevelopmental Milestones Checklist
ECenteric coated
EC9595% maximal effective concentration
EEethinyl estradiol
ePPNDenhanced pre- and postnatal development
FDAU.S. Food and Drug Administration
FDCfixed-dose combination
GBSgroup B streptococcus
GMCgeometric mean concentration
gpglycoprotein
HAVhepatitis A virus
HBIGhepatitis B immune globulin
HBcAbhepatitis B core antibody
HBeAbhepatitis B e antibody
HBeAghepatitis B e antigen
HBsAbhepatitis B surface antibody
HBsAghepatitis B surface antigen
HBVhepatitis B virus
HCVhepatitis C virus
HCAZhead circumference–for–age z-scores
HEUHIV exposed but uninfected
HDhigh dose
HDPhypertensive disorders of pregnancy
HUUHIV unexposed and uninfected
HRhazard ratio
HRSAHealth Resources and Services Administration
HSRhypersensitivity reaction
IC50inhibitory concentration 50%
IDSAInfectious Diseases Society of America
IGFinsulin-like growth factor
IgGimmunoglobulin G
IgMimmunoglobulin M
IMintramuscular
INSTIintegrase strand transfer inhibitor
IPVintimate partner violence
IQRinterquartile range
IRRincidence rate ratio
IDSAInfectious Diseases Society of America
IUDintrauterine device
IUPCintrauterine pressure catheter
IVintravenous/intravenously
LAlong-acting    
LARClong-acting reversible contraceptive
LAZlength-for-age z-scores
LBWlow birth weight
LGBTQIA+lesbian, gay, bisexual, transgender, queer, intersex, asexual, and gender nonconforming
mtDNAmitochondrial DNA
NATnucleic acid test
NEnorethindrone
NAT2N-acetyltransferase 2
NHSSNational HIV Surveillance System
NICHDEunice Kennedy Shriver National Institute of Child Health and Human Development    
NIHNational Institutes of Health
NNRTInon-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor
nPEPnon-occupational post-exposure prophylaxis
NPHIVnon–perinatally acquired HIV
NRTInucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NTDneural tube defect
OARACOffice of AIDS Research Advisory Council
OIopportunistic infection
ORodds ratio
The PanelThe Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission
PBMCperipheral blood mononuclear cells
PBphysiologically based    
PBPKphysiologically based pharmacokinetic
PJPPneumocystis jirovecii pneumonia
PCRpolymerase chain reaction
PHIVperinatally acquired HIV
PIprotease inhibitor
PI/rritonavir-boosted protease inhibitor
PKpharmacokinetic
POorally
POCpoint of care
POPprogesterone-only oral contraceptive pill
PPIproton pump inhibitor
PrEPpre-exposure prophylaxis
PSEDProfile of Social Emotional Development
PTBpreterm birth
RAMresistance-associated mutation
RCTrandomized controlled trial
RDSrespiratory distress syndrome
ROMrupture of membranes
RRrelative risk
SGAsmall for gestational age
SQsubcutaneous
sPTBspontaneous preterm birth
STIsexually transmitted infection
t1/2appterminal-phase half-life
TBtuberculosis
Tdaptetanus, diphtheria and pertussis
TDMtherapeutic drug monitoring
UGTuridine diphosphate glucuronosyltransferase
vPTBvery preterm birth
VLviral load
vSGAvery small for gestational age
WAZweight-for-age z-scores
WHOWorld Health Organization
XRextended release

Download Guidelines